Fragile X syndrome and the amygdala

被引:19
作者
Suvrathan, Aparna [1 ]
Chattarji, Sumantra [1 ]
机构
[1] Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India
关键词
MENTAL-RETARDATION PROTEIN; LONG-TERM DEPRESSION; KNOCKOUT MOUSE MODEL; FEAR MEMORY; INHIBITORY CIRCUITS; SYNAPTIC PLASTICITY; GABA(A) RECEPTOR; MICE LACKING; FMR1; POTENTIATION;
D O I
10.1016/j.conb.2011.04.005
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Fragile X syndrome (FXS) is the most commonly inherited form of mental impairment and autism. Current understanding of the molecular and cellular mechanisms underlying FXS symptoms is derived mainly from studies on the hippocampus and cortex. However, FXS is also associated with strong emotional symptoms, which are likely to involve changes in the amygdala. Unfortunately, the synaptic basis of amygdalar dysfunction in FXS remains largely unexplored. Here we describe recent findings from mouse models of FXS that have identified synaptic defects in the basolateral amygdala that are in many respects distinct from those reported earlier in the hippocampus. Long-term potentiation and surface expression of AMPA-receptors are impaired. Further, presynaptic defects are seen at both excitatory and inhibitory synapses. Remarkably, some of these synaptic defects in the amygdala are also amenable to pharmacological rescue. These results also underscore the need to modify the current hippocampus-centric framework to better explain FXS-related synaptic dysfunction in the amygdala.
引用
收藏
页码:509 / 515
页数:7
相关论文
共 50 条
  • [21] Which Comes First in Fragile X Syndrome, Dendritic Spine Dysgenesis or Defects in Circuit Plasticity?
    Portera-Cailliau, Carlos
    [J]. NEUROSCIENTIST, 2012, 18 (01) : 28 - 44
  • [22] The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome
    Hampson, David R.
    Adusei, Daniel C.
    Pacey, Laura K. K.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2011, 81 (09) : 1078 - 1086
  • [23] Channelopathies and dendritic dysfunction in fragile X syndrome
    Brager, Darrin H.
    Johnston, Daniel
    [J]. BRAIN RESEARCH BULLETIN, 2014, 103 : 11 - 17
  • [24] The challenges of clinical trials in fragile X syndrome
    Jacquemont, Sebastien
    Berry-Kravis, Elizabeth
    Hagerman, Randi
    von Raison, Florian
    Gasparini, Fabrizio
    Apostol, George
    Ufer, Mike
    Des Portes, Vincent
    Gomez-Mancilla, Baltazar
    [J]. PSYCHOPHARMACOLOGY, 2014, 231 (06) : 1237 - 1250
  • [25] Dysregulation and restoration of homeostatic network plasticity in fragile X syndrome mice
    Jewett, Kathryn A.
    Lee, Kwan Young
    Eagleman, Daphne E.
    Soriano, Stephanie
    Tsai, Nien-Pei
    [J]. NEUROPHARMACOLOGY, 2018, 138 : 182 - 192
  • [26] Functional consequences of postnatal interventions in a mouse model of Fragile X syndrome
    Rais, Maham
    Lovelace, Jonathan W.
    Shuai, Xinghao S.
    Woodard, Walker
    Bishay, Steven
    Estrada, Leo
    Sharma, Ashwin R.
    Nguy, Austin
    Kulinich, Anna
    Pirbhoy, Patricia S.
    Palacios, Arnold R.
    Nelson, David L.
    Razak, Khaleel A.
    Ethell, Iryna M.
    [J]. NEUROBIOLOGY OF DISEASE, 2022, 162
  • [27] Potential therapeutic interventions for fragile X syndrome
    Levenga, Josien
    de Vrij, Femke M. S.
    Oostra, Ben A.
    Willemsen, Rob
    [J]. TRENDS IN MOLECULAR MEDICINE, 2010, 16 (11) : 516 - 527
  • [28] Dysregulation of mTOR Signaling in Fragile X Syndrome
    Sharma, Ali
    Hoeffer, Charles A.
    Takayasu, Yukihiro
    Miyawaki, Takahiro
    McBride, Sean M.
    Klann, Eric
    Zukin, R. Suzanne
    [J]. JOURNAL OF NEUROSCIENCE, 2010, 30 (02) : 694 - 702
  • [29] Lithium: A Promising Treatment for Fragile X Syndrome
    Liu, Zhonghua
    Smith, Carolyn Beebe
    [J]. ACS CHEMICAL NEUROSCIENCE, 2014, 5 (06): : 477 - 483
  • [30] Fragile X Syndrome in children
    Acero-Garces, David O.
    Saldarriaga, Wilmar
    Cabal-Herrera, Ana M.
    Rojas, Christian A.
    Hagerman, Randi J.
    [J]. COLOMBIA MEDICA, 2023, 54 (02):